

AD _____

Award Number: DAMD17-01-1-0149

TITLE: Tamoxifen Dependent Interaction Between the Estrogen
Receptor and a Novel P21 Activated Kinase

PRINCIPAL INVESTIGATOR: Steven P. Balk, M.D., Ph.D.

CONTRACTING ORGANIZATION: Beth Israel Deaconess Medical Center
Boston, Massachusetts 02215

REPORT DATE: June 2002

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE			Form Approved OMB No. 074-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503				
1. AGENCY USE ONLY (Leave blank)	2. REPORT DATE June 2002	3. REPORT TYPE AND DATES COVERED Annual (1 Jun 01 - 31 May 02)		
4. TITLE AND SUBTITLE Tamoxifen Dependent Interaction Between the Estrogen Receptor and a Novel P21 Activated Kinase		5. FUNDING NUMBERS DAMD17-00-1-0114		
6. AUTHOR(S) Steven P. Balk, M.D., Ph.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Beth Israel Deaconess Medical Center Boston, Massachusetts 02215 E-Mail: sbalk@caregroup.harvard.edu		8. PERFORMING ORGANIZATION REPORT NUMBER		
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012		10. SPONSORING / MONITORING AGENCY REPORT NUMBER		
11. SUPPLEMENTARY NOTES		20021113 027		
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited			12b. DISTRIBUTION CODE	
13. Abstract (<i>Maximum 200 Words</i>) (<i>abstract should contain no proprietary or confidential information</i>) The estrogen receptor α (ER α) plays an important role in breast cancer and a large fraction of ER α positive breast cancers respond to tamoxifen. We cloned a novel p21 activated kinase (PAK), termed PAK6, which binds to the androgen receptor (AR) and selectively to the tamoxifen liganded ER α . PAKs are a family of serine/threonine kinases that bind to and are regulated by the Rho family small (p21) GTPases, Cdc42 and Rac. PAKs are involved in translating extracellular signals into cellular responses. Although PAK6 binds to Cdc42, it lacks the Cdc42 regulated autoinhibitory domain found in other PAKs and can instead be activated by steroid receptor binding. Binding is mediated by at least two sites on PAK6, one at the N-terminus and another towards the middle of the protein. PAK6 inhibits ER α and AR transcriptional activity. PAK6 is highly expressed in brain and testes, is also expressed in mammary epithelium and prostate, and its expression in breast cancer cell lines has been confirmed by a polyclonal antibody. Further studies of PAK6 protein expression in breast cancer are in progress, and breast cancer cell lines expressing wildtype and mutant PAK6 have been generated to assess functions in breast cancer.				
14. SUBJECT TERMS estrogen receptor, tamoxifen, kinase, Cdc42, breast cancer			15. NUMBER OF PAGES 20	
			16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

Table of Contents

Cover.....	1
SF 298.....	2
Table of Content.....	3
Introduction.....	4
Body.....	4
Key Research Accomplishments.....	5
Reportable Outcomes.....	5
Conclusions.....	5
References.....	5
Appendices.....	6

INTRODUCTION

The classical estrogen receptor, estrogen receptor α (ER α) plays an important role in breast cancer development and a large fraction of ER α positive breast cancers respond to treatment with tamoxifen. We have cloned a novel p21 activated kinase (PAK), termed PAK6, which binds to the androgen receptor (AR) and selectively to the 4-hydroxytamoxifen (OHT) liganded ER α . PAKs are a family of serine/threonine kinases that bind to and are regulated by the active (GTP bound) form of the Rho family small (p21) GTPases, Cdc42 and Rac. PAK6 is expressed in normal mammary epithelium and in breast cancer cell lines, and its expression may be modified in breast cancer. Taken together, these results support a role for PAK6 in breast cancer. The purpose of this research is to test the major hypothesis that PAK6, through interactions with the ER α , contributes to the development of breast cancer. A second hypothesis to be tested is that the OHT dependent ER α -PAK6 interaction contributes to the therapeutic effect of OHT in breast cancer and the subsequent development of OHT resistance. The specific aims are 1) to determine the structure, cellular distribution, and activation state of endogenous PAK6 protein in normal breast and breast cancer cell lines; 2) to determine whether PAK6 contributes to ER α function and cell growth in breast cancer cell lines; and 3) to determine whether PAK6 contributes to tamoxifen sensitivity in breast cancer

BODY

Over the past year we have completed and published the data on PAK6 cloning and on its interaction with the ER α (Lee et al., 2002, enclosed). The data in this report also address aspects of PAK6 functional interaction with steroid hormone receptors. Additional not yet published data relevant to each of the proposed tasks are detailed below.

Task 1. Determine the structure, cellular distribution, and activation state of endogenous PAK6 protein in normal breast and breast cancer cell lines

- a. Develop PAK6 antibodies (months 1-12)**
- b. Assess endogenous PAK6 using these antibodies (months 6-24)**
- c. Clone and sequence endogenous PAK6 from breast cancer cell lines (months 1-12)**

Rabbit polyclonal antibodies have been generated against PAK6 using a GST-PAK6 fusion protein. These antibodies recognize a single protein of 75 kDa in PAK6 transfected cells. The antibodies have been used to assess endogenous PAK6 protein expression in breast cancer cells. By immunoprecipitation and immunoblotting, the antibodies recognize a protein of approximately 75 kDa in MCF7 cells, consistent with PAK6. Interestingly, the antibodies also recognize a second band of approximately 65 kDa in MCF7 cells, but not in prostate cancer cells or in PAK6 transfected cells. Studies are ongoing using antibodies and cloning to determine whether this lower band represents an alternative form of PAK6. The antisera is also being affinity purified for immunohistochemistry on clinical breast cancer samples.

Task 2. Determine whether PAK6 contributes to ER α function and cell growth in breast cancer cell lines

- a. Develop anti-sense methods to downregulate PAK6 (months 6-24)**
- b. Develop dominant negative PAK6 constructs (months 1-18)**
- c. Assess the functional consequences of blocking PAK6 (months 12-36)**

The initial efforts have been to develop dominant negative PAK6 constructs. By site directed mutagenesis we have generated vectors encoding PAK6 mutants that are constitutively active or kinase dead, as well as constructs that no longer bind Cdc42. In preliminary transient transfection studies these have inhibited androgen receptor function similarly to the wild type. Stable MCF7 cell transfectants expressing these mutant proteins have now been generated and are currently being examined functionally.

Task 3. Determine whether PAK6 contributes to tamoxifen sensitivity in breast cancer

a. Determine whether tamoxifen blocks PAK6 activation (months 18-30)

b. Determine whether the tamoxifen-ER α -PAK6 complex mediates cell cycle arrest (months 12-24)

Although this task was proposed to be carried out later, we have generated MCF7 cell lines expressing increased levels of wild type and mutant PAK6 proteins. Using these cells, studies are being done to assess whether the PAK6 expression alters responses to tamoxifen.

KEY RESEARCH ACCOMPLISHMENTS

- PAK6 cloning
- demonstration of PAK6 interaction with ER α and AR
- identification of second binding site in PAK6 N-terminus
- generation of PAK6 antibodies
- demonstration of PAK6 protein in breast and prostate cancer cells
- generation of PAK6 mutants
- generation of MCF7 cell lines expressing increased levels of wild type and mutant PAK6

REPORTABLE OUTCOMES

manuscript: Lee et al., 2002 (appended)

cell lines: MCF7 cells expressing wild type or mutant PAK6

antibodies: polyclonal rabbit anti-PAK6 antibodies

CONCLUSIONS

During the past year we have completed and published our initial studies describing PAK6 and its interaction with the ER α and AR. Over the past year we have also generated a series of reagents that were needed to further address the functional significance of PAK6 and its interactions with steroid hormone receptors. These materials include PAK6 specific antibodies, mutants, and cell lines. Studies using these reagents to complete the tasks outlined above are in progress.

REFERENCES

Lee SR, Ramos SM, Ko A, Masiello D, Swanson KD, Lu ML, and Balk SP. 2002. AR and ER Interaction with a p21-Activated Kinase (PAK6). Mol Endo 16:85-99

APPENDICES

manuscript: Lee et al., 2002

AR and ER Interaction with a p21-Activated Kinase (PAK6)

SUZANNE R. LEE, SHARON M. RAMOS, ANDREW KO, DAVID MASIELLO,
KENNETH D. SWANSON, MICHAEL L. LU, AND STEVEN P. BALK

Cancer Biology Program, Hematology-Oncology Division (S.R.L., S.M.R., A.K., D.M., K.D.S., S.P.B.), Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215; and Urology Division (M.L.L.), Department of Surgery, Brigham and Women's Hospital, Boston, Massachusetts 02115

A human protein termed p21-activated kinase 6 (PAK6), based on homology to the PAK family of serine/threonine kinases, was cloned as an AR interacting protein. PAK6 was a 75-kDa protein with a predicted N-terminal Cdc42/Rac interactive binding domain and a C-terminal kinase domain. PAK6 bound strongly to GTP-Cdc42 and weakly to GTP-Rac. In contrast to most PAKs, kinase activity was not stimulated by Cdc42 or Rac, but could be stimulated by AR binding. PAK6 interacted with the intact AR in a mammalian one-hybrid assay and bound *in vitro*, without ligand, to the hinge region between the AR DNA- and ligand-binding domains. PAK6 also bound to the ER α , and binding was enhanced by 4-hydroxytamoxifen. AR and ER α transcriptional activities were inhibited by PAK6 in

transient transfections with episomal and integrated reporter genes. AR inhibition was not reversed by transfection with an activated Cdc42 mutant, Cdc42V12, which by itself also inhibited AR transactivation. Epitope-tagged PAK6 was primarily cytoplasmic in the absence or presence of AR and hormone. PAK6 transcripts were expressed most highly in brain and testis, with lower levels in multiple tissues including prostate and breast. PAK6 interaction provides a mechanism for cross-talk between steroid hormone receptors and Cdc42-mediated signal transduction pathways and could contribute to the effects of tamoxifen in breast cancer and in other tissues. (*Molecular Endocrinology* 16: 85-99, 2002)

THE AR is a steroid hormone receptor member of the larger nuclear receptor family that mediates the biological functions of androgens (1, 2). In addition to its physiological roles in many tissues, the AR also plays a central role in prostate cancer development and progression (3, 4). The steroid hormone receptors share a relatively conserved central DNA binding domain (DBD) and a C-terminal ligand binding domain (LBD), which also has a ligand-dependent transactivation function (referred to as AF-2). Their N-termini are more diverse, but generally possess an independent transactivation function (AF-1), with the AR N-terminal domain being particularly large and having a strong AF-1. Hormone binding causes conformational changes that result in receptor dissociation from an HSP90 chaperone complex, homodimerization, and the generation of a binding site for proteins containing leucine-x-x-leucine-leucine (LXXLL) motifs, including

the p160 family of steroid receptor coactivator (SRC) proteins (5-7). The SRC proteins appear to be the major coactivators mediating the ligand-dependent AF-2 transactivation function of the LBD, through histone acetyl or methyltransferase activity and association with cAMP response element binding protein or p300. The SRC proteins can also interact directly with the N terminus of steroid hormone receptors, and this interaction may be particularly critical for the AR (8-11).

In addition to the p160 steroid receptor coactivator proteins, there is a growing list of proteins that interact with the N-terminal, DNA, or ligand binding domains of steroid hormone receptors (5, 6). These include proteins linked to the general transcriptional machinery, proteins that function as transcriptional coactivators or corepressors by other mechanisms, and proteins the functions of which remain to be determined. Some of these interactions are regulated by ligand binding and mediated by LXXLL or related motifs, while others are independent of ligand. There is also a ligand-dependent interaction between N-terminal and C-terminal domains of the AR and other steroid hormone receptors, which appears to be particularly important for AR transactivation (12-18). Finally, there is evidence for nontranscriptional functions of steroid hormone receptors (19-21) and an association between the ER α and PI3K (22).

Abbreviations: ARE, Androgen response element; BIC, bicalutamide; CDS, charcoal dextran-stripped; CRIB, Cdc 42/Rac interactive binding; DBD, DNA-binding domain; DHT, dihydrotestosterone; DTT, dithiothreitol; ERE, estrogen response element; EST, expressed sequence tag; GFP, green fluorescent protein; GRIP, GR-interacting protein; GST, glutathione-S-transferase; LBD, ligand-binding domain; mAb, monoclonal antibody; MBP, myelin basic protein; MMTV-LTR, mouse mammary tumor virus-long terminal repeat; NLS, nuclear localization signal; OHT, 4-hydroxytamoxifen; PAK, p21-activated kinase; SRC, steroid receptor coactivator.

This report describes the isolation and characterization of an AR and ER α interacting protein termed p21-activated kinase 6 (PAK6), based upon its homology to previously identified PAKs. PAKs form an evolutionarily conserved family of serine/threonine kinases that bind to, and are regulated by, the active (GTP-bound) form of the Rho family small (p21) GTPases, Cdc42 and Rac (23–26). Cdc42 and Rac binding are mediated by a conserved N-terminal Cdc42/Rac interactive binding (CRIB) domain (27). PAKs are presumed to mediate some of the downstream effects of activated Cdc42 and Rac, although the targets of their kinase activity and precise functions remain to be determined. The yeast PAK homolog (*STE20*) activates a MAPK kinase kinase analogous to mammalian Raf (28), and mammalian PAKs have been reported to similarly activate MAPK pathways in response to activated Cdc42 and/or Rac (29–34). Additional possible roles for PAKs are in cytoskeleton organization (35–37), cell cycle regulation (38), heterotrimeric G protein signaling (39), and apoptosis (40–43). Therefore, the AR- and ER α -PAK6 interactions provide potential direct links between these steroid hormone receptors and signal transduction pathways regulating diverse cellular functions.

RESULTS

Isolation of a PAK-Related Kinase Interacting with the AR in Yeast

A fragment of the human AR containing the DNA and ligand binding domains (AR505–919), was fused to the GAL4 DNA binding domain and used as the bait in a series of yeast two-hybrid screens, in the presence of 1 μ M dihydrotestosterone (DHT). Positive clones were subsequently screened without DHT, and several clones that showed strong DHT-dependent growth were isolated and sequenced. Two clones contained in-frame fusions to previously identified proteins, gelsolin, an actin-binding protein (44), and ARA70. ARA70 (fused at alanine 168) was identified previously as an AR interacting protein, although its functional significance remains unclear (45, 46). The significance of the AR interaction with gelsolin was also unclear, although an AR interaction with another actin-binding protein, filamin, was recently reported (47).

Partial sequencing of a third isolate (clone 56) indicated that it was a novel protein. A specific interaction between the AR and clone 56 in yeast was confirmed by cotransforming clone 56 (fused to the GAL4 transactivation domain) with additional plasmids encoding GAL4 DNA-binding domain (GAL4 DBD) fusion proteins and assessing β -galactosidase production from an integrated GAL4 responsive reporter. In the absence of DHT, only low levels of β -galactosidase activity were detected in all cases (not shown). DHT increased β -galactosidase activity 27-fold in yeast expressing both clone

56 and the GAL4 DBD-AR (505–919) fusion protein used in the yeast screen (Table 1). This level of induction was greater than that seen with a transactivation domain fused to GR interacting protein 1 (GRIP1) (563–1121), which contains three LXXLL motifs and an additional AR-interacting domain (48). In contrast, no induction was observed when clone 56 was expressed with GAL4 DBD fusion proteins containing the AR N-terminal transactivation domain, AR (2–506), the DBD and nuclear localization signal (NLS), AR (553–635), or with the irrelevant protein cortactin. These results demonstrated that the protein encoded by clone 56 interacted with the AR in yeast and that the interaction required a region C-terminal to the NLS.

Sequence Analysis of Full-Length PAK6

Complete sequencing of clone 56 revealed a consensus kinase domain at the C terminus, but no homology to previously reported proteins at the amino terminus (Fig. 1A). However, the first 35 nucleotides of the cDNA insert (nucleotides 874–908, boxed in Fig. 1A) were identical to the 3'-end of an expressed sequence tag (EST) from a testis cDNA library (GenBank accession no. AA815255), indicating that this EST encoded the 5'-end of clone 56. The plasmid containing this EST was obtained and sequenced to provide the 5'-end of the transcript. The assignment of the initiation methionine was based upon an in-frame stop codon (tga) 39 bases upstream (Fig. 1A, boxed). Since the overlap between the EST and clone 56 was only 35 bases immediately before a poly A tract in the EST, RT-PCR was used to confirm that this EST represented the 5'-end of the clone 56 transcript. RT-PCR from prostate cancer-derived cDNAs using 5'-primers derived from the EST and 3'-primers from clone 56 generated a product of the predicted size and sequence (data not shown), confirming that EST AA815255 represented the 5'-end of clone 56.

The full-length sequence predicted a protein of 681 amino acids with a molecular mass of 75 kDa (Fig. 1A). Analysis of the full-length coding region revealed homology at the 5'- and 3'-ends to the PAK family of serine/threonine kinases, of which four had been previously reported in humans (24, 37, 49–51). The sequences of two additional human PAK-related pro-

Table 1. AR Interaction with Clone 56 in Yeast

Bait	Prey	Fold Induction
pAS2-AR(2–506)	pACT2 clone 56	1.1
pAS2-AR(553–635)	pACT2 clone 56	0.9
pAS2-AR(505–919)	pACT2 clone 56	27
pAS2 vector	pACT2 clone 56	1.2
Cortactin	pACT2 clone 56	1.0
pAS2-AR(505–919)	GRIP1(563–1121)	5.7

Fold induction is based on β -galactosidase activity minus vs. plus 1 μ M DHT. GRIP1 was in pGAD24.

A

ggcagcagcctctcctcagcgcctaagagagagggccagtcggtg**tgaggagtcgcgaggaagaggcggaaggcgccggaaggcacc** 88

M F R K K K K K R P E **I S A P Q N F Q H R V H T S** F D P K E 30
 atgttcgcgcaagaaaagaacgcccctgagatctcagcgcacagaaactccagcaccgtgtccacacctccttcgaccccaagaa 178
 G K F V G L P P Q W Q N I L D T L R R P K P V V D P S R I T 60
 ggcaagtttgggtctcccccaacaatggcagaacatcctggacacactgcggcgcccaagcccggtgtggacccttcggaatcaca 268
 R V Q L Q P M K T V V R G S A M P V D G Y I S G L L N D I Q 90
 cggtgcagctccagcccatgaagacagtggtgctggggcagcgcgatgctgtggtggtacatctcggggtgctcaacgacatccag 378
 K L S V I S S N T L R G R S P T S R R R A Q S L G L L G D E 120
 aagttgtcagtcacgtcccaacaccctgcgtggcgcagccccaccagccggcgccggcgacagtccttgggggtgctgggggatgag 468
 H W A T D P D M Y L Q S P Q S E R T D P H G L Y L S C N G G 150
 cactgggcccaccgacacatgtacctccagagccccagctgtgagcgcactgacccccagccctctacctcagctgcaacgggggc 558
 T P A G H K Q M P W P E P Q S P R V L P N G L A A K A Q S L 180
 acaccagcagggccacaagcagatgcgtggcccgagccacagacccagggctcctgcccattgggtgtgctgcaaaggacagtcctgt 648
 G P A E F Q G A S Q R C L Q L G A C L Q S S P P G A S P P T 210
 ggccccgcggagtttcaggtgctcgcagcgtgtctgcagctgggtgctgctgcagagctccccaccagagcctgcgccccccag 738
 G T C N R H G M K A A K H G S E E A R P Q S C L V G S A T G R 240
 ggcacnaataggcaggaatgaaggctgccaagcagctgtgagggagggccggccacagtcctgctgtgtgggtcagccacaggcagg 828
 P G G E G S P S P K T R E S S L K R R L F R S M F L S T A A 270
 ccagtggtgggaaggcagccctagccctaagaccgggagagcagc**ctgaagcgcaggctattccgaagcatgttctcgtgctcactgtgcc** 918
 T A P P S S S K P G P P P Q S K P N S S F R P P P Q K D N P 300
 acagccctccaagcagcagcaagccagggccctccaccacagagcaagcccaactcctcttccgaccgcccagaaagacaacccccca 1008
 S L V A K A Q S L P S D Q P V G T F S P L T T S D T S S P Q 330
 agccctgggtgccaagccagctccttgcctcgaccagccggtggggactctcagccctcgaccacttcggataccagcagcccccag 1098
 K S L R T A P A T G Q L P G R S S P A G S S P R T W H A Q I S 360
 aagtcctccgcagaccccgccacagggcagcttccagggcgttctcccccaggggattccccccgacctggcagcggccagatcagc 1188
 T S N L Y L P Q D P T V A K G A L A G E D T G V V T H E Q F 390
 accagcaactgtacctgccccagggaccccggttgcgaaggtgccccgtggtgtgagggacacaggtgtgtgtgacacatgagcagttc 1278
 K A A L R M V V D Q G D P R I L L D S Y V K I **G E G S T G** I 420
 aaggtcgcgtcaggtggtgtgtggacaggggtgacccccgggtgctgctgtggacagctacgtgaagattggcgaggggtccaccggc 1368
V C L A R E K H S G R Q V A V K M M D L R K Q Q R R E L F 450
 gtcgtgtggcccgaggaagcactcgggcccaggtggcggtcaagatgagtgagcaggaagcagcagcagcagggagctgtcttc 1458
 N **E V I M R D Y Q H F N V V E M Y K N Y L V G E E L W V** 480
 aacgaggtgtgatcagcgggactaccagcactcaacgtgtgtgagatgtacaagaactacctggtggcgagggagctgtgtgtgtgtc 1548
 M E F L Q G G A L T D I V S Q V R L N E E Q I A T V C E A V 510
 atggagttctcagggaggagccctcacagacatcgtctcccaagtcagggtgaatgaggagcagattgccactgtgtgtgtgtgtgtgtg 1638
 L Q A L C A Y L H A Q G V I H R **D I K S** D S I L L T L D G R V 540
 ctgcagccctggcctacctgcatgctcaggtgtcatccacgggacatcaagagtgactccatcctgctgaccctcgatggcaggggtg 1728
 K L S **D F G** F C A Q I S K D V P K R K S L V G T P Y W M A P 570
 aagctctcggacttcggtattctgtgtcagatcagcaagagcgtccctcaagaggaagtccttgggtgggaacccctactggatggctcct 1818
E V I S R S L Y A T E V D I W S L G I M V I E M V D G E P 600
 gaagtgtatctccaggtctttgtatgactgaggtggtatctgtgtctgtggcatcatggtgattgagatggttagatgggagccaccg 1908
 Y F S D S P V Q A M K R L R D S P P P K L K N S H K V S P V 630
 tactcagtgatccccagtgcaagcagtgctcggggacagcccccccaagctgaaaaactctcacaaggtctccccagtg 1998
 L R D F L E R M L V R D P Q E **R** A T A Q E L L D H P F L L Q 660
 ctgcgagacttccctggagcggatgctgtgtgcccccaagagagagccacagccagagctcctagaccaccccttctgtgtgcag 2088
 T G L P E C **L V P L I Q L Y** R K Q T S T C * 681
 acagggctacctgagtgctgtgctgctcagctctaccgaaagcagacccctcactgctgagccaccccaagtatgctgtccac 2178


B

CRIB Domain
ISXPXFXHXXHVG

PAK6	1-MFRKKKKRPEISAPQNFQHRVHTSFDPKEGKFVGLPPQWQNIL-DTLR
PAK5	1-..G....I-..G.S..E....G...Q.Q..T...Q..HSL.A..AN
PAK4	1-..G.R.RV-.....S..E....G..QH.Q..T...R...SLIEESA.
PAK3	59-TNK..E.E....L.SD.E.TI.VG..AVT.E.T.I.E..ARL.QTSNI
PAK2	63-GSK..E.E....P.SD.E.TI.VG..AVT.E.T.M.E..ARL.QTSNI
PAK1	64-TNK..E.E....L.SD.E.TI.VG..AVT.E.T.M.E..ARL.QTSNI
	β1 β2 H1
PAK6	RKPVVVDPSRITRVQLQPMKTVVRGSAMPVDGYISGLLNDIQKLSVIS
PAK5	M....C..PI..A....NKPKETS.N...E.FDNI..TR
PAK4	L...AC..SI.PGAP..I....KGAK..ALT..DEFENM..TR
PAK3	TKLEQKNPQAVLDV.KFYDSKETVNNQKYMST..DKSAHGYYIAHP
PAK2	TKLEQKNPQAVLDV.KFYDSN-TV-KQKYLSTPPEKDGFLPSGTPAL
PAK1	TKSEQKNPQAVLDV.EFYNSKKTNSQKYMSTDKSAE.YNSSNALN
	H2 H3 *

Fig. 1. Complete Sequence of PAK6 and Homology to Other PAKs

A, PAK6 nucleotide and predicted amino acid sequence. An in-frame stop codon (tga) 5' of the predicted initiation ATG and the N-terminal CRIB domain are boxed. Nucleotides at the 5'-end of yeast clone 56 that were identical to the 3'-end of the EST from a testis library (nucleotides 874–908) are also boxed. Amino acids highly conserved in all kinase domains are boxed. S531, which is an asparagine in most other kinases, is boxed and in bold. A possible heterotrimeric G protein-binding site is boxed at the C terminus. B, Homology in CRIB and autoinhibitory domains. The alignments are based on PAK6 with periods (.) indicating identical residues and dashes (–) marking gaps introduced to maximize homology. PAK1–3 have an N-terminal extension past the CRIB domain that is absent in PAK4–6. β-Strands (β1 and β2) and α-helices (H1–3) are from the PAK1 crystal structure. Residues underlined in the CRIB domain mediate dimerization. The autoinhibitory lysine in PAK1–3 is indicated by an asterisk (*).



I

Human Multi-Tissue Blot




Fig. 2. PAK6 Cell and Tissue Distribution

A–D, HeLa cells transiently transfected with GFP-PAK6 (pEGFP-PAK6) alone (A and C) or cotransfected with the pSVAR₀ expression vector (B and D). E–H, HeLa cells transiently transfected with GFP-AR (pEGFP-AR) alone (E and G) or cotransfected with pcDNA-PAK6 (F and H). Cells were in steroid hormone-depleted medium (A, B, E, and F) or were treated for 30 min with 10 nM DHT (C, D, G, and H). I, Multiple tissue expression array probed with unique ³²P-labeled fragment of PAK6. Column 1 (A–H),




Fig. 3. Mammalian One-Hybrid Analysis of PAK6-AR Binding

CV1 cells were cotransfected with ARE₄-Luc reporter (100 ng), pRL-SV40 (Renilla control), and with the pSVAR₀ (200 ng), VP16-PAK6(256–681) (20 ng), or VP16-SRC(595–780) (20 ng), as indicated. DHT was added at 24 h, and cells were harvested at 48 h and assayed for luciferase and Renilla activity.

teins, termed PAK5 and PAK6, were more recently deposited in GenBank. The protein isolated here was identical to PAK6, located on chromosome 15q15.

The N terminus of PAK6 had homology with the CRIB domains of the previously characterized PAKs, containing six of eight of the CRIB domain consensus residues (Fig. 1B) (27). The greatest homology was with PAK4 (37) and PAK5, also with CRIB domains at the immediate N terminus. The recently reported crystal structure of human PAK1 indicated that this protein formed a dimer through an antiparallel β -ribbon formed by a β -strand that overlapped the CRIB domain (β 1 in Fig. 1B) (52). The critical contact residues in this β -strand are conserved in PAK1–6 (*underlined* in the CRIB consensus in Fig. 1B), suggesting that PAK6 is similarly a dimer. The PAK1 crystal structure also showed that the autoinhibition of PAK1 kinase activity was due to a bundle of three helices (H1–3 in Fig. 1B) that packed against the kinase domain and positioned a lysine residue (amino acid 141 in PAK1, indicated with an *asterisk*) into the active site. These structural features were highly conserved in PAK1–3, but were not evident in PAK4–6, suggesting alternative

mechanisms for regulating the kinase activity of these latter PAKs.

The C terminus of PAK6 encoded a consensus kinase domain with homology to PAK1, 2, and 3 (50% compared with PAK1), but again with much greater homology to PAK4 (80% homology). Residues highly conserved in kinase domains were also conserved in PAK6 (Fig. 1A, *boxed*), with the exception of an asparagine that was replaced by a serine (S531), a replacement also seen in PAK4 (*boxed and in bold* in Fig. 1A). Other conserved structural features of previously described PAK family members include N-terminal proline-rich SH3-binding motifs, which can target PAKs to the membrane through the Nck adapter protein (31, 53–55), and a heterotrimeric G protein β -subunit binding domain at the C terminus (39, 56). The former N-terminal SH3-binding motifs were not present in PAK4, 5, or 6, as the CRIB domains were at the extreme N terminus. Three of the four residues defining a putative heterotrimeric G protein binding motif were present in the C terminus of PAK6 (Fig. 1A, *boxed*).

Cell and Tissue Distribution of PAK6

The full-length PAK6 was fused to the C-terminus of green fluorescent protein (GFP) and used to assess cellular distribution. The GFP-PAK6 fusion protein transfected into HeLa cells localized primarily to the plasma membrane and cytoplasm (Fig. 2A). PAK6 remained primarily cytoplasmic when cotransfected with the AR, in the absence (Fig. 2B) or presence of DHT (Fig. 2D). HeLa cells were similarly transfected with a GFP-AR expression vector to assess PAK6 effects on AR distribution. The AR in HeLa cells was primarily cytoplasmic in the absence of DHT (Fig. 2, E and F) and nuclear in the presence of DHT (Fig. 2, G and H). This distribution was not altered by PAK6 cotransfection (Fig. 2, F and H). Similar results were obtained by indirect immunofluorescence with AR and an epitope-tagged PAK6, indicating that cellular localization was not altered by the GFP fusion (data not shown).

Hybridization of a unique internal fragment from PAK6 (nucleotides 451–1256) to a human multiple tissue expression array revealed the strongest expres-

Whole brain, cerebral cortex, frontal lobe, parietal lobe, occipital lobe, temporal lobe, paracentral gyrus of the cerebral cortex, pons. Column 2 (A–H), Blank, right cerebellum, corpus callosum, amygdala, caudate nucleus, hippocampus, medulla oblongata, putamen. Column 3 (A–E), Substantia nigra, nucleus accumbens, thalamus, pituitary gland, spinal cord; F–H, blank. Column 4 (A–H), Heart, aorta, left atrium, right atrium, left ventricle, right ventricle, interventricular septum, apex of heart. Column 5 (A–H), Esophagus, stomach, duodenum, jejunum, ileum, ileocecum, appendix, ascending colon. Column 6 (A–C), Transverse colon, descending colon, rectum; D–H, blank. Column 7 (A–H), kidney, skeletal muscle, spleen, thymus, peripheral blood leukocyte, lymph node, bone marrow, trachea. Column 8 (A–H), Lung, placenta, bladder, uterus, prostate, testis, ovary, blank. Column 9 (A–F), Liver, pancreas, adrenal gland, thyroid gland, salivary gland, mammary gland; G and H, blank. Column 10 (A–H), Promyelocytic leukemia (HL-60), HeLa S3, chronic myelogenous leukemia (K-562), lymphoblastic leukemia (MOLT-4), Burkitt's lymphoma (Raji), Burkitt's lymphoma (Daudi), colorectal adenocarcinoma (SW480), lung carcinoma (A549). Column 11 (A–H), Fetal brain, fetal heart, fetal kidney, fetal liver, fetal spleen, fetal thymus, fetal lung, blank. Negative controls: Column 12 (A–H), Yeast total RNA, yeast tRNA, *E. coli* rRNA, *E. coli* DNA, poly r(A), human C α t-1 DNA, 100 ng human DNA, 500 ng human DNA.




Fig. 4. PAK6 Binds to the AR

A, GST, GST-GRIP1(624–1122), or GST-PAK6(256–681) were used to pull down 35 S-labeled AR, plus or minus DHT (10 nM) or BIC (10 or 50 μ M), as indicated. B, Lysates from LNCaP cells grown in medium with 10% FCS were precipitated with GST, GST-GRIP1(624–1122), or GST-PAK6(256–681), and bound AR was detected by immunoblotting. C, LNCaP cells grown in medium with 10% CDS FCS or in this medium with 10 nM DHT or 5 μ M BIC added overnight were lysed in glycerol lysis buffer, precipitated with GST-PAK6(256–681) or GST beads (25 μ g each), and AR immunoblotted. D, 35 S-labeled full-length PAK6 was precipitated with the indicated GST-AR fusion proteins. E, 35 S-labeled full-length PAK1 or PAK6 was precipitated with GST, GST-AR(505–919), or GTP-loaded GST-Cdc42V12. The input lanes contain 10% of the material incubated with the beads.

sion in testis and in many areas of the brain, particularly cortical structures (Fig. 2I). Lower level expression was seen in prostate, thyroid, adrenals, placenta, kidney, esophagus, mammary gland, and heart. There was little or no detectable expression in ovary, uterus, intestine, liver, lung, spleen, thymus, peripheral blood leukocytes, lymph node, or bone marrow.

PAK6 Binding to the AR in Mammalian Cells and *in Vitro*

PAK6 binding to the AR in mammalian cells was assessed by fusing the VP16 transactivation domain to the N-terminal of the PAK6 fragment isolated from the yeast screen, VP16-PAK6(256–681). DHT induced AR transcription 60-fold from a luciferase reporter gene regulated by a multimerized androgen response element (ARE₄) (Fig. 3). Cotransfection with vectors encoding only the VP16 activation domain (AASVVP16) or a VP16-SRC1(595–780) fusion, containing the first LXXLL motif of SRC-1, were used as negative controls as this region of SRC-1 was shown previously to interact very weakly or not at all with the AR (10, 11, 16). Both vectors markedly repressed AR activity (Fig. 3

and data not shown), likely reflecting competition for transcription factors by the noninteracting VP16 transactivation domain. In contrast, cotransfection with the VP16-PAK6(256–681) vector increased the induction to 175-fold. These results indicated that PAK6 interacted with the intact ligand-bound AR on DNA in mammalian cells.

AR binding to PAK6 was next assessed *in vitro* by precipitation with a series of glutathione-S-transferase (GST) fusion proteins. The fragment of PAK6 isolated in the yeast screen was expressed as a GST fusion protein, GST-PAK6(256–681), and full-length 35 S-labeled AR was generated by coupled *in vitro* transcription/translation. AR binding to GST-PAK6(256–681) was compared with binding to a GST-GRIP1(624–1122) fusion protein, containing multiple LXXLL motifs and shown to interact with agonist-bound LBDs of nuclear receptors including the AR (48, 57). AR binding to the GST-GRIP1(624–1122) fusion protein was detectable, but was very weak (Fig. 4A). Binding was not enhanced by DHT, which may reflect nonnative folding of the *in vitro*-generated AR. In contrast, full-length AR was precipitated efficiently by the GST-PAK6(256–681) fusion protein. The binding was ligand




Fig. 5. PAK6 Binds to the ERα

A, The indicated GST fusion proteins were used to pull down ³⁵S-labeled ERα in the presence of 10 nM E2 (E₂), 20 μM or 100 μM OHT, or no added hormone. B, GST, GST-GTP-Cdc42V12, or GST-ERα(281–595) were used to pull down full-length ³⁵S-labeled PAK6, in the presence or absence of the indicated hormones.

independent as it did not require added DHT and was not blocked by bicalutamide (BIC), a competitive antagonist of DHT binding and AR function (58).

GST-PAK6(256–681) pull-down experiments were next carried out using the endogenous AR from LNCaP cells, the only generally available AR-expressing human prostate cancer cell line. LNCaP cells express a mutant AR (T877A) that still responds to DHT but has altered responses to other ligands and AR antagonists (59). LNCaP lysates were precipitated by GST-PAK6(256–681), GST-GRIP1(624–1122), or control GST beads, and AR was detected by immunoblotting. The results similarly demonstrated specific binding of the intact AR to PAK6 (Fig. 4B). In these experiments comparable binding to the GST-GRIP1(624–1122) control was observed, possibly reflecting native folding and androgen binding by the AR *in vivo*. The hormone dependence of binding by the LNCaP AR was further assessed by culturing the cells overnight in medium with charcoal dextran-stripped (CDS) FCS (steroid hormone-depleted medium), or with added DHT (10 nM) or BIC (5 μM), which is also an antagonist of the LNCaP AR. GST-PAK6(256–681) bound specifically to the AR from DHT, BIC, and untreated (CDS) LNCaP cells (Fig. 4C), further demonstrating that binding was not ligand dependent.

Binding of full-length PAK6 to AR was investigated using ³⁵S-PAK6, which was labeled by coupled *in vitro* transcription/translation. Strong binding was observed to a GST-AR(505–919) fusion protein, containing the DBD, hinge, and LBD (Fig. 4D). Binding was also detected to deletion mutants GST-AR(634–804), with the LXXLL binding AF-2 removed, and to GST-AR(634–668). The GST-AR(634–668) protein corresponds to a fragment from the AR nuclear localization signal (amino acids 617–633) to the beginning of helix 3, which marks the beginning of the LBD. These latter results indicated that PAK6 bound to a site distinct from the LXXLL motif binding AF-2 and suggested that binding was through the hinge region between the DBD and LBD.

Finally, the specificity of the PAK6-AR interaction was assessed by examining GST-AR binding to PAK1. In contrast to the results with PAK6, there was no specific binding of *in vitro*-transcribed/translated PAK1 to the GST-AR(505–919) fusion protein (Fig. 4E). However, PAK1 was found to bind to a GTP-loaded GST-Cdc42 fusion protein (see below). This result indicated that the AR interaction was not a general property of PAKs.

PAK6 Binding to ERα

The ERα was next examined to determine whether PAK6 binding was specific for the AR. ³⁵S-Labeled ERα, generated by *in vitro* transcription/translation in rabbit reticulocyte lysates, bound specifically to the positive control GST-GRIP1(624–1122) fusion protein (Fig. 5A). This GRIP1 binding in the absence of added estrogen likely reflected estrogen in the rabbit reticulocyte lysate and could be augmented with added E2. As expected, ERα binding to GST-GRIP1(624–1122) was markedly reduced by the partial agonist 4-hydroxytamoxifen (OHT). A comparable level of ERα binding to GST-PAK6(256–681) was observed in the absence or presence of E2. However, in marked contrast to GST-GRIP1 results, ERα binding to PAK6 was enhanced (3.4-fold) by OHT (Fig. 5A). This latter finding was consistent with the AR results and indicated that PAK6 bound to a site distinct from the agonist-generated LXXLL coactivator binding site, as this site is occluded in the OHT-bound ERα (60–62).

It was next determined whether full-length PAK6 bound specifically to the ERα. These experiments used a GST-ERα(281–595) fusion protein, encompassing the region C terminal to the NLS and the complete ERα LBD, and shown previously to bind LXXLL containing coactivator proteins in an agonist-dependent manner (63). Full-length *in vitro*-transcribed/translated PAK6 bound specifically to the GST-ERα(281–595) fusion protein in the absence of added E2, and binding was not augmented by added E2 (Fig. 5B). Moreover, consistent with the results above, binding was enhanced (2.7-fold) by OHT. PAK6 binding by the OHT-ligated GST-ERα was comparable to

the CRIB domain-mediated binding of GST-GTP-Cdc42V12 (see below).

PAK6 Interaction with p21 GTPases

It was next determined whether PAK6 had a functional CRIB domain capable of binding to GTP-Cdc42 and/or -Rac. These experiments used a full-length PAK6 cDNA with a C-terminal myc/his epitope tag, constructed in the pcDNA3 mammalian expression vector. GST pull-down experiments were carried out using GTPase-deficient (activated) Cdc42V12 and RacV12 mutants expressed as GST fusion proteins. Equal amounts of GST fusion proteins bound to glutathione agarose beads were first loaded with GTP. Comparable GTP loading was confirmed on parallel samples using 32 P-GTP (not shown). The beads were then used to precipitate the myc/his-tagged PAK6 from transfected CV1 cell lysates. GST-GTP-Cdc42V12 pulled down a substantial amount of PAK6, identified as a 75-kDa protein by immunoblotting with an anti-myc monoclonal antibody (mAb) (Fig. 6A). In contrast, only very weak binding to GST-GTP-RacV12 was detected, although this binding appeared to be specific as no binding was detected to either an inactive control (GST-RacN17) or to other control GST proteins.

GTP-Cdc42 or -Rac binding activates the kinase activity of other PAKs by blocking an autoinhibitory domain carboxy to the CRIB domain (Fig. 1B) (52, 64-66). However, this domain appears to be absent in PAK4-6 (see Fig. 1B), and PAK4 kinase activity is not stimulated by Cdc42 (37). Therefore, kinase assays were carried out to assess PAK6 activation by GTP-Cdc42. For these experiments, full-length 35 S-labeled PAK6 was expressed *in vitro* and precipitated by a series of GST fusion proteins bound to glutathione beads. The kinase activity of the precipitated proteins was compared with proteins precipitated by the same beads from a control unprogrammed rabbit reticulocyte lysate, using myelin basic protein (MBP) as a substrate. No kinase activity was detected in the GST-GTP-Cdc42V12 precipitate (Fig. 6B, top panel), although PAK6 binding to these beads was confirmed by recovery of the labeled PAK6 protein (Fig. 6B, bottom panel). There was also no detectable kinase activity or PAK6 binding to GST-Rac fusion proteins.

Kinase activity was precipitated by the GST-AR(505-919) fusion protein from the unprogrammed and PAK6 programmed lysates (Fig. 6B). However, the kinase activity from the PAK6 programmed lysate was consistently greater (~3-fold). This indicated that it reflected PAK6 kinase activity, or possibly PAK6 activation of another AR-associated kinase, stimulated by AR binding. It is not yet clear whether the lower levels of kinase activity precipitated from the unprogrammed lysate were due to an endogenous PAK or other kinases. Taken together, these results demonstrated that the PAK6 CRIB domain was functional with respect to p21 binding, with a marked preference for




Fig. 6. PAK6 Binding by p21 GTPase and Kinase Activation

A, GST fusion proteins were used to pull down myc-tagged PAK6 from a transfected CV1 cell lysate. Equivalent amounts of GST fusion proteins loaded with GTP were used as indicated, and precipitated PAK6 was detected by immunoblotting with an anti-myc mAb. GST-CD1d is an irrelevant control fusion protein. Lysate alone (2% of the material used for each pull down) is shown in the first lane, and the position of the full-length PAK6 (75 kDa) is indicated. B, PAK6 programmed or unprogrammed rabbit reticulocyte lysates (PAK6 +/-, respectively) were pulled down with the indicated AR or GTP-loaded GST fusion proteins. The precipitates were then split in half and analyzed for kinase activity with MBP substrate (top panel), or analyzed for bound 35 S-PAK6 (bottom panel).

binding GTP-Cdc42 vs. GTP-Rac. The results further indicated that PAK6 kinase activity was not regulated by Cdc42 binding, with the data suggesting instead a role for AR in regulating PAK6 kinase activity.

PAK6 Inhibition of AR and ER α Transcriptional Activity

Cotransfection experiments were carried out to determine whether PAK6 could modulate the transcriptional activity of the AR. Cells were cotransfected with an ARE₄-luciferase reporter plasmid, AR expression vector (pSVAR₀) (67), pcDNA-PAK6 or control (pcDNA-LacZ) expression vectors, and an internal control Renilla vector (pRL-SV40). AR transcriptional activity was stimulated 33-fold by DHT in the absence of PAK6 and was not inhibited by the control pcDNA-LacZ vector (Fig. 7A). In contrast, AR transcriptional activity was markedly inhibited by PAK6, with induction reduced approximately 5-fold by 200 ng of the PAK6 vector. This inhibition was not a nonspecific effect on transcription or on the pSV promoter regulating the AR, as expression of the control Renilla reporter regulated by a pSV promoter was unaffected by PAK6 (Fig. 7B). Immunoblotting for AR protein further showed that the




Fig. 7. PAK6 Inhibition of AR Transcriptional Activity

A, CV1 cells were transiently transfected with an ARE₄-luciferase reporter (100 ng), pRL-SV40 (0.2 ng), pSVAR₀ (200 ng), and pcDNA-LacZ or pcDNA-PAK6 expression vectors. Luciferase and Renilla activity were assessed after 24 h ± DHT. B, Renilla activity from the experiment in panel A. C, AR expression in lysates from the cells used in panel A.

inhibition was not due to decreased AR protein expression (Fig. 7C).

The effect of PAK6 on transcription from another AR-responsive promoter, the mouse mammary tumor virus long terminal repeat (MMTV-LTR) containing two steroid response elements recognized by the AR, was next examined. DHT stimulated AR transcriptional activity on the MMTV-LTR-luciferase reporter by 5.3-fold (Fig. 8A). Similar to the above result with the ARE₄ reporter, this DHT-stimulated activity was inhibited by cotransfection with PAK6. It was also determined whether PAK6 affected AR transcriptional activity in the more physiological setting of an integrated ARE. For this experiment, CV1 cells were stably transfected with the MMTV-LTR-luciferase reporter plasmid, in conjunction with a neomycin resistance plasmid. G418-resistant clones were then screened for ligand-




Fig. 8. PAK6 Inhibition of AR on Episomal and Integrated MMTV-LTR

A, CV1 cells were transiently transfected with an MMTV-LTR-luciferase reporter. Cotransfected plasmids and DHT treatments were as in Fig. 7. B, CV1(MMTV-Luc) cells were cotransfected with AR, Renilla, and PAK6 plasmids and treated with DHT as in panel A.

dependent stimulation of luciferase activity by transfected AR, and a clone with a low level of background luciferase activity and a relatively high level of DHT-inducible AR activity was selected. DHT augmented the transcriptional activity of the transfected AR by approximately 6-fold in these cells (Fig. 8B). This was reduced to 2.4-fold induction by cotransfection with PAK6, indicating that PAK6 could inhibit AR activity on an integrated as well as an episomal reporter.

Similar cotransfection experiments were carried out with an ER α expression vector and an estrogen responsive element (ERE)-regulated luciferase reporter plasmid to determine whether PAK6 modulated ER α transcriptional activity. Luciferase activity was stimulated about 4.5-fold by E2 (Fig. 9A). Cotransfection with PAK6 reduced this stimulation by approximately 50%, while a control LacZ vector had no effect. This result demonstrated a similar inhibitory effect of PAK6 on AR and ER α transcriptional activity.

As PAK6 also binds to GTP-Cdc42, it was possible that AR and ER α inhibition by PAK6 was due to sequestration of GTP-Cdc42 rather than a direct interaction. This was addressed by cotransfection with activated (GTPase-deficient) Cdc42V12. DHT stimulated AR transactivation by 26-fold, and this was re-




Fig. 9. PAK6 Inhibition of ER α and Effect of Cdc42

A, CV1 cells were transiently transfected with an ERE₂-luciferase reporter (100 ng), pRL-SV40 (0.2 ng), pcDNA-ER α (200 ng), and pcDNA-LacZ or pcDNA-PAK6 expression vectors. Luciferase and Renilla activities were assessed after 24 h $\pm$ E2 (10 nM). B, CV1 cells were transfected and treated as in Fig. 7, with the addition of a pCDNA-Cdc42V12 expression plasmid as indicated. Results in this experiment were not corrected for Renilla, as Cdc42V12 at the high concentration decreased Renilla activity.

duced to approximately 7-fold by PAK6 (Fig. 9B). This repression by PAK6 was not reversed by cotransfected Cdc42V12. Moreover, transfection of Cdc42V12 by itself inhibited AR transcriptional activity, consistent with a recent report that Rho GTPases can negatively regulate steroid hormone receptors (68). Therefore, these results demonstrated that AR inhibition by PAK6 was not due to sequestration of Cdc42.

DISCUSSION

This study identified PAK6 as a strongly AR-interacting protein in a yeast two-hybrid screen. The physiological significance of the interaction was supported by *in vitro* studies demonstrating specific binding of the full-length AR and PAK6 proteins and by mammalian one-

hybrid experiments demonstrating an interaction between the ligated native AR and a VP16-PAK6 fusion protein. PAK6 also bound to ER α , and this binding was enhanced by OHT, indicating that the interaction was sensitive to the functionally critical conformational changes in the AF-2 region that mediate coactivator binding to the ER α and to other nuclear receptors in response to ligand (61, 62, 69, 70).

The enhanced ER α binding with OHT further indicated that the PAK6 interaction was not through the LXXLL binding AF-2 region, as this site is occluded in the OHT-bound ER α (62). This was consistent with the ligand independence of AR binding *in vitro* and results using GST-AR deletion mutants that indicated a binding site in the hinge region between the DBD and LBD. A number of other proteins appear to bind to this region of the AR and/or other steroid hormone receptors, including ANPK (a nuclear serine/threonine kinase) (71), L7/SPA (72), and UBC9 (a SUMO conjugating enzyme) (73). Although these proteins can function as coactivators, a deletion in the hinge region enhances AR transcriptional activity (74). Moreover, mutations at the C terminus of the AR hinge region have been identified in human prostate cancers and in an SV40 T/t antigen-induced mouse prostate cancer (75), with the latter mutation enhancing AR transcriptional activity, consistent with a corepressor binding to this region.

AR transcriptional activity from two different episomal reporter genes, as well as an integrated reporter, was inhibited by PAK6. Inhibition was not due to Cdc42 sequestration by the PAK6 CRIB domain, as it was not reversed by cotransfected Cdc42V12. Moreover, Cdc42V12 by itself inhibited AR transcriptional activity. This latter result was consistent with a previous report showing that Rho GDI α , a negative regulator of Rho GTPases, could augment AR, ER α , ER β , and GR transcriptional activity, and that the ER was inhibited by Rho, Rac, and Cdc42 (68). Taken together, these results suggest that the AR transcriptional inhibition by PAK6 could be due to recruitment of Cdc42 to the AR complex. However, PAK6 is unlikely to mediate all of the effects of Rho GTPases on steroid hormone receptors, as it interacted only weakly with GTP-Rac.

Alternatively, PAK6 inhibition of the AR may be mediated by phosphorylation of the AR or other AR-associated proteins. Studies addressing possible substrates for PAK6 kinase activity are underway but have not found AR phosphorylation by PAK6 *in vitro* or increased AR phosphorylation *in vivo* in response to transfected PAK6. Other possible mechanisms for AR inhibition by PAK6 are that PAK6 competes with coactivators for binding, stabilizes the AR in a conformation unfavorable for coactivator binding, or blocks the interaction between the AR N-terminal domain and LBD (12–18). These latter mechanisms would be consistent with the enhanced PAK6 binding to the OHT-ligated ER α , as OHT blocks coactivator binding. Finally, it should of course be emphasized that AR

inhibition may reflect nonphysiological high levels of transfected PAK6, and that PAK6 may instead selectively modulate AR activity on particular promoters or in response to activation of other signal transduction pathways.

Alternative functions for the PAK6-AR interaction may be to recruit PAK6 and/or activate its kinase activity. The kinase activity of most previously characterized PAKs is blocked by an autoinhibitory domain that follows the CRIB domain (52, 64–66). Cdc42 or Rac binding relieves this inhibition and results in PAK autophosphorylation and activation of kinase activity. Although PAK6 clearly has a functional CRIB domain, which selectively binds to Cdc42, there is limited homology between PAK6 and human PAK1–3 in the CRIB-regulated autoinhibitory domain (see Fig. 1B), and PAK6 kinase activity is not activated by GTP-Cdc42 binding. The N terminus of PAK6 is homologous to PAK4, which also selectively binds to Cdc42 and is not activated by Cdc42 binding (37). Studies are underway to determine whether, and under what conditions, the AR can activate PAK4 or PAK6 kinase activity *in vivo*, as suggested by the *in vitro* kinase activity associated with PAK6 bound to a GST-AR fusion protein. This kinase activity could contribute to the rapid nontranscriptional activation of MAPKs and other pathways demonstrated previously for ER α (19, 20) and AR (21).

The cellular distribution of transfected PAK6, plus or minus cotransfected AR, was primarily in the cytoplasm and on plasma membrane. However, lower levels of nuclear PAK6, alone or in association with AR, could not be ruled out. Preliminary biochemical fractionation studies similarly indicate that PAK6 is mostly cytoplasmic but suggest that a small fraction might be nuclear. The highest levels of PAK6 expression were in brain and testis, although PAK6 could also be expressed at relatively high levels by specific cell types in other tissues. While this manuscript was under revision, another group similarly identified PAK6 as an AR-interacting protein that was highly expressed in testis and could repress AR transcriptional activity, although their data indicated marked AR stimulated nuclear translocation of transfected PAK6 (76). It is clear that specific antibodies will be needed to better assess the cellular and tissue distribution of the endogenous protein.

Database searches have not revealed definite homologs of PAK6 in other species. However, the mushroom bodies tiny (*mbt*) gene from *Drosophila* encodes a PAK that appears related to human PAK4, 5, and 6 (77). Mutations in *mbt* interfere with brain development, which in conjunction with the high level expression of PAK6 in human adult and fetal brain, suggest a role for PAK6 in brain development. In this regard, a PAK3 mutation has been identified in a family with mental retardation (51). However, although the biological functions of PAK6 remain unclear, they likely differ in detail from most previously described PAKs based upon low-sequence

homology, the absence of SH3 binding motifs that direct binding of the Nck adapter protein (31, 53–55) or the Pix/Cool nucleotide exchange proteins (78, 79), and the failure of GTP-Cdc42 to activate PAK6 kinase activity. PAK6 binding may be a mechanism through which diverse signal transduction pathways, in particular those mediated through Cdc42, can modulate the activity of the AR and ER α (and possibly other nuclear receptors). Alternatively, or in addition, PAK6 binding may mediate nontranscriptional functions of the AR or ER α . Finally, while the OHT-enhanced PAK6-ER α interaction may or may not be physiological, it could contribute to the therapeutic effects of OHT in breast cancer and in other tissues.

MATERIALS AND METHODS

PAK6 Cloning

A fragment of the human AR from glycine 505 to the C terminus (AR505–919) was generated by PCR and cloned into the pAS2 yeast GAL4 DNA binding domain vector (CLONTECH Laboratories, Inc., Palo Alto, CA). A series of human GAL4 activation domain libraries were screened in the presence of 1 μ M DHT, and a fragment of PAK6 was isolated from a prostate library in the pACT2 vector (clone 56). A plasmid containing the N terminus of PAK6, identified as an EST from a testis library (GenBank accession no. AA815255), was obtained from the I.M.A.G.E. (Integrated Molecular Analysis of Genomes and their Expression) consortium. Additional AR yeast vectors, as indicated, were constructed by PCR and confirmed by DNA sequencing. pGAD24-GRIP(563–1121) was from Michael Stallcup (University of Southern California, Los Angeles) (57). Liquid β -galactosidase assays were carried out on extracts from transformed yeast containing an integrated GAL4 promoter regulating β -galactosidase (strain HF7c) (CLONTECH Laboratories, Inc.) with *O*-nitrophenyl- β -D-galactopyranoside as the substrate, as described by the manufacturer.

PAK6 Expression Vectors

Full-length PAK6 was assembled from three fragments in the pcDNA3.1(–)/Myc-His C mammalian expression vector, containing C-terminal myc and histidine epitope tags (Invitrogen, Carlsbad, CA). The 5′-end through an internal XbaI site was obtained from the I.M.A.G.E. consortium plasmid described above, a middle fragment from the XbaI site to a downstream BamHI site was generated by PCR amplification from prostate cancer cDNA, and a fragment from the BamHI site to the 3′-end was from the yeast clone 56. The pcDNA 3.1 epitope tag (myc-his) was placed in frame at the C terminus by cutting at a BspI site in the PAK6 stop codon and a downstream KpnI site in the pcDNA polylinker, followed by blunting with mung bean nuclease and ligation.

The GFP-PAK6 vector (pEGFP-PAK6) was constructed in the pEGFP-C1 vector (CLONTECH Laboratories, Inc.). An oligonucleotide encoding the first 11 amino acids of PAK6 with a C-terminal BglII site was ligated to the BglII site encoding amino acids 11 and 12 in PAK6. This was then excised and an N-terminal HindIII site introduced by the oligonucleotide was used to ligate PAK6 in frame at the C terminus of GFP as a HindIII-KpnI fragment. A GFP-AR expression vector (pEGFP-AR) was similarly constructed in pEGFP-C1, but using an EagI site located eight amino acids from the N terminus of the AR. To generate GST-PAK6 (256–681), an XhoI site was introduced into the pGEX-2TK polylinker, and

the entire PAK6 fragment from clone 56 was inserted in frame using a compatible *SaI* site in pACT2 at the junction between the GAL4 activation domain and PAK6.

PAK6 Expression

pEGFP-PAK6, with or without pSVAR_o, was transfected into HeLa cells by electroporation. Cells were then plated onto coverslips, cultured for 24 h in DMEM with 10% charcoal-dextran stripped FCS (HyClone Laboratories, Inc., Logan, UT), treated for varying times with DHT, and fixed in 1% paraformaldehyde in PBS. HeLa cells were similarly transfected with pEGFP-AR, with or without the pcDNA-PAK6 expression vector. A human multitissue blot containing polyadenylated RNA from multiple different human tissues and cell lines (Human Multiple Tissue Expression Array, CLONTECH Laboratories, Inc.) was probed with a PCR-generated ³²P-labeled fragment of PAK6 corresponding to amino acids 115–383 (having no homology to previously described PAKs or other proteins). Hybridization and washing conditions were as recommended by the manufacturer.

GST Fusion Proteins and Pull Downs

GST-AR fusion proteins were constructed in pGEX-2TK by PCR amplification and confirmed by sequencing (80). GST-GRIP1(624–1122) and GST-ER(281–595) (63) were from Myles Brown (Dana Farber Cancer Institute, Boston, MA). GST-RacV12, -RacN17, and -Cdc42V12 mutant constructs were from Chris Carpenter (Beth Israel Deaconess Medical Center, Boston, MA) (81). For GTP loading, the GST-RacV12 and GST-Cdc42V12 fusion proteins bound to glutathione agarose beads (5 µg) were initially incubated in 20 mM Tris, pH 7.5, 100 mM NaCl, 1 mM EDTA, and 1 mM dithiothreitol (DTT), with a 10-fold molar excess of GTPγS, for 15 min at 30°C. The beads were then placed on ice, and MgCl₂ was added to a concentration of 5 mM. After 5 min on ice, the beads were pelleted and lysates were added. GTP loading was comparable for the Rac and Cdc42 fusion proteins, based upon [³²P]GTP binding in parallel experiments.

For GST pull-down experiments, CV1 cells were transfected in 10-cm plates with 10 µg of PAK6 in pcDNA3.1(–)/Myc-His C, using Lipofectamine according to the manufacturer's directions (Life Technologies, Inc., Gaithersburg, MD). Transfected CV1 cells or LNCaP prostate carcinoma cells (with endogenous AR) were lysed in 50 mM Tris, pH 7.6, 150 mM NaCl, 5 mM MgCl₂, 0.5% Triton X-100, 5 mM DTT, and protease inhibitors for 15 min at 4°C, followed by centrifugation to remove nuclei. Lysates were then incubated with GST fusion proteins (5 µg except where indicated) bound to glutathione agarose beads for 2–4 h at 4°C, followed by washes in lysis buffer and elution in SDS-PAGE sample buffer. In the indicated experiments lysis and washes were in 10 mM Tris, pH 7.5, 150 mM NaCl, 1 mM MgCl₂, 1 mM EGTA, 1 mM DTT, 10% glycerol, 0.1% Triton X-100, and protease inhibitors (glycerol lysis buffer). PAK6 was detected by immunoblotting with mouse anti-myc mAb 9E10, and AR was detected with a mixture of rabbit anti-AR antibodies against N and C-terminal peptides (all from Santa Cruz Biotechnology, Inc., Santa Cruz, CA).

³⁵S-labeled proteins were generated by *in vitro* transcription/translation (TNT T7 Quick Coupled Transcription/Translation System, Promega Corp., Madison, WI). AR, ERα (from Myles Brown, Dana Farber Cancer Institute), PAK1, and PAK6 plasmids (in pGEM3 or pcDNA, 2 µg) in 50 µl of reticulocyte lysate with 20 µCi of ³⁵S-methionine were incubated at 30°C for 1 h, according to the manufacturer's directions. GST fusion proteins (5 µg on glutathione agarose beads) were mixed with 10 µl of the programmed lysate in 0.5 ml of PBS, pH 7.4, 1 mM DTT, and protease inhibitors. After 2–4 h at 4°C, the beads were washed in the same buffer, except with 0.05% NP-40. Proteins were eluted in SDS-

PAGE sample buffer, and labeled proteins were detected with a PhosphorImager (Molecular Dynamics, Inc., Sunnyvale, CA). DHT was obtained from Sigma, OHT was from Alexis Biochemicals, and bicalutamide was kindly provided by Astra Zeneca Pharmaceuticals (Wilmington, DE).

Kinase Assays

Beads with precipitated proteins were washed once in kinase buffer (40 mM HEPES, pH 7.4, 20 mM MgCl₂) and then re-suspended in 30 µl of kinase buffer with MBP (5 µg) (Sigma), 10 µCi [³²P]ATP (3000 Ci/mmol), and 20 µM cold ATP. Reactions were carried out at room temperature for 15 min and stopped with SDS-PAGE loading buffer containing 10 mM EDTA. Labeled MBP was analyzed on 15% SDS-PAGE.

AR and ERα Transcriptional Activity

Transient transfections to assess AR transcriptional activity were carried out using CV1 cells in 24-well plates (58, 82). Cells were transfected using LipofectAMINE or LipofectAMINE 2000 (Life Technologies, Inc.) with AR expression vector (pSVAR_o) (67), a Renilla expression vector to control for transfection efficiency (pRL-CMV or pRL-SV40, Promega Corp.), and PAK6 or other experimental or control plasmids as indicated. The VP16-SRC(595–780) encodes the first nuclear receptor binding domain of SRC-1 fused to the C terminus of the VP16 activation domain in the AASVVP16 vector (83). A VP16-PAK6(256–681) expression vector was generated in AASVVP16 by PCR to generate an in-frame *EcoRI* site at amino acid 256 in PAK6 and a *HindIII* site at the 3'-end. The fragment was then cloned at the 3'-end of VP16 as an *EcoRI-HindIII* fragment. The reporter plasmids were an androgen-responsive luciferase reporter construct driven by synthetic AREs and a minimal promoter (ARE₄-luciferase) or MMTVpA3Luc, driven by the androgen-responsive MMTV-LTR (83). The ARE₄-luciferase reporter was constructed by inserting four tandem ARE repeats (5'-TGACAGGATGT-TCTGAATTCATGTACAGGATGTTCT-3') in front of an E1b minimal TATA box sequence, followed by a firefly luciferase gene. After the 24-h transfection, cells were cultured for another 24 h in DMEM with 5% CDS FCS, with or without added 10 nM DHT. Lysates were assayed for luciferase activity and Renilla activity using a dual luciferase kit (Promega Corp.), and luciferase activity was normalized for Renilla to give relative light units.

ERα transcriptional activity was assessed similarly using a pcDNA3.1-ERα expression vector and a luciferase reporter gene, ERE₂TK-Luc, regulated by two copies of the ERE from the vitellogenin gene (kindly provided by Myles Brown, Dana Farber Cancer Institute). The ERα experiments were done in phenol red-free medium. All points were in triplicate or quadruplicate and mean ± SEM are shown.

Additional experiments used CV1 cells containing an integrated luciferase reporter gene regulated by the androgen responsive MMTV-LTR. These CV1(MMTV-Luc) cells were generated by transfecting CV1 cells with an MMTV-LTR-luciferase reporter plasmid (MMTVpA3Luc) (83) and neomycin resistance plasmid, and selecting for G418-resistant cells. A series of clones were then screened to identify ones with low background luciferase activity and high level androgen-dependent AR induction.

Acknowledgments

We thank Drs. C. Carpenter and A. Hollenberg for reagents and very helpful discussions, and Drs. A. Brinkmann, M. Brown, M. Stallcup, W. Chin, and R. Pestell for reagents.

Received February 7, 2001. Accepted September 14, 2001.

Address all correspondence and requests for reprints to: Steven P. Balk, Hematology-Oncology Division, Beth Israel Deaconess Medical Center, HIM Building-Room 1050, 330 Brookline Avenue, Boston, Massachusetts 02215. E-mail sbalk@caregroup.harvard.edu.

This work was supported by NIH Grants R01-CA-65647 (S.P.B.), T32-AI-07542 (S.M.R.), HL-07623, R29-GM-54713 (M.L.L.), a Department of Defense Breast Cancer Research grant (to S.P.B.), and by the Hershey Family Prostate Cancer Research Fund.

REFERENCES

- Quigley CA, De Bellis A, Marschke KB, el Awady MK, Wilson EM, French FS 1995 Androgen receptor defects: historical, clinical, and molecular perspectives. *Endocr Rev* 16:271–321
- Brinkmann AO, Blok LJ, de Ruiter PE, Doesburg P, Steketeer K, Berrevoets CA, Trapman J 1999 Mechanisms of androgen receptor activation and function. *J Steroid Biochem Mol Biol* 69:307–313
- Bubley GJ, Balk SP 1996 Treatment of androgen-independent prostate cancer. *Oncologist* 1:30–35
- Taplin ME, Bubley GJ, Ko YJ, Small EJ, Upton M, Rajeshkumar B, Balk SP 1999 Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. *Cancer Res* 59:2511–2515
- Glass CK, Rose DW, Rosenfeld MG 1997 Nuclear receptor coactivators. *Curr Opin Cell Biol* 9:222–232
- McKenna NJ, Lanz RB, O'Malley BW 1999 Nuclear receptor coregulators: cellular and molecular biology. *Endocr Rev* 20:321–344
- Freedman LP 1999 Increasing the complexity of coactivation in nuclear receptor signaling. *Cell* 97:5–8
- Webb P, Nguyen P, Shinsako J, Anderson C, Feng W, Nguyen MP, Chen D, Huang SM, Subramanian S, McKinerney E, Katzenellenbogen BS, Stallcup MR, Kushner PJ 1998 Estrogen receptor activation function 1 works by binding p160 coactivator proteins. *Mol Endocrinol* 12:1605–1618
- Onate SA, Boonyaratankornkit V, Spencer TE, Tsai SY, Tsai MJ, Edwards DP, O'Malley BW 1998 The steroid receptor coactivator-1 contains multiple receptor interacting and activation domains that cooperatively enhance the activation function 1 (AF1) and AF2 domains of steroid receptors. *J Biol Chem* 273:12101–12108
- Bevan CL, Hoare S, Claessens F, Heery DM, Parker MG 1999 The AF1 and AF2 domains of the androgen receptor interact with distinct regions of SRC1. *Mol Cell Biol* 19:8383–8392
- Alen P, Claessens F, Verhoeven G, Rombauts W, Peeters B 1999 The androgen receptor amino-terminal domain plays a key role in p160 coactivator-stimulated gene transcription. *Mol Cell Biol* 19:6085–6097
- Wong CI, Zhou ZX, Sar M, Wilson EM 1993 Steroid requirement for androgen receptor dimerization and DNA binding. Modulation by intramolecular interactions between the NH2-terminal and steroid-binding domains. *J Biol Chem* 268:19004–19012
- Kraus WL, McKinerney EM, Katzenellenbogen BS 1995 Ligand-dependent, transcriptionally productive association of the amino- and carboxyl-terminal regions of a steroid hormone nuclear receptor. *Proc Natl Acad Sci USA* 92:12314–12318
- Langley E, Zhou ZX, Wilson EM 1995 Evidence for an anti-parallel orientation of the ligand-activated human androgen receptor dimer. *J Biol Chem* 270:29983–29990
- Ikonen T, Palvimäki JJ, Janne OA 1997 Interaction between the amino- and carboxy-terminal regions of the rat androgen receptor modulates transcriptional activity and is influenced by nuclear receptor coactivators. *J Biol Chem* 272:29821–29828
- Berrevoets CA, Doesburg P, Steketeer K, Trapman J, Brinkmann AO 1998 Functional interactions of the AF-2 activation domain core region of the human androgen receptor with the amino-terminal domain and with the transcriptional coactivator TIF2 (transcriptional intermediary factor2). *Mol Endocrinol* 12:1172–1183
- He B, Kemppainen JA, Voegel JJ, Gronemeyer H, Wilson EM 1999 Activation function 2 in the human androgen receptor ligand binding domain mediates interdomain communication with the NH2-terminal domain. *J Biol Chem* 274:37219–37225
- He B, Kemppainen JA, Wilson EM 2000 FXXLF and WXXLF sequences mediate the NH2-terminal interaction with the ligand binding domain of the androgen receptor. *J Biol Chem* 275:22986–22994
- Castoria G, Barone MV, Di Domenico M, Bilancio A, Ametrano D, Migliaccio A, Auricchio F 1999 Non-transcriptional action of oestradiol and progestin triggers DNA synthesis. *EMBO J* 18:2500–2510
- Chen Z, Yuhanna IS, Galcheva-Gargova Z, Karas RH, Mendelsohn ME, Shaul PW 1999 Estrogen receptor α mediates the nongenomic activation of endothelial nitric oxide synthase by estrogen. *J Clin Invest* 103:401–406
- Peterziel H, Mink S, Schonert A, Becker M, Klocker H, Cato AC 1999 Rapid signalling by androgen receptor in prostate cancer cells. *Oncogene* 18:6322–6329
- Simoncini T, Hafezi-Moghadam A, Brazil DP, Ley K, Chin WW, Liao JK 2000 Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. *Nature* 407:538–541
- Manser E, Leung T, Salihuddin H, Zhao ZS, Lim L 1994 A brain serine/threonine protein kinase activated by Cdc42 and Rac1. *Nature* 367:40–46
- Martin GA, Bollag G, McCormick F, Abo A 1995 A novel serine kinase activated by rac1/CDC42Hs-dependent autophosphorylation is related to PAK65 and STE20. *EMBO J* 14:4385
- Knaus UG, Morris S, Dong HJ, Chernoff J, Bokoch GM 1995 Regulation of human leukocyte p21-activated kinases through G protein-coupled receptors. *Science* 269:221–223
- Bagrodia S, Cerione RA 1999 Pak to the future. *Trends Cell Biol* 9:350–355
- Burbelo PD, Drechsel D, Hall A 1995 A conserved binding motif defines numerous candidate target proteins for both Cdc42 and Rac GTPases. *J Biol Chem* 270:29071–29074
- Herskowitz I 1995 MAP kinase pathways in yeast: for mating and more. *Cell* 80:187–197
- Zhang S, Han J, Sells MA, Chernoff J, Knaus UG, Ulevitch RJ, Bokoch GM 1995 Rho family GTPases regulate p38 mitogen-activated protein kinase through the downstream mediator Pak1. *J Biol Chem* 270:23934–23936
- Polverino A, Frost J, Yang P, Hutchison M, Neiman AM, Cobb MH, Marcus S 1995 Activation of mitogen-activated protein kinase cascades by p21-activated protein kinases in cell-free extracts of *Xenopus* oocytes. *J Biol Chem* 270:26067–26070
- Lu W, Katz S, Gupta R, Mayer BJ 1997 Activation of Pak by membrane localization mediated by an SH3 domain from the adaptor protein Nck. *Curr Biol* 7:85–94
- Frost JA, Steen H, Shapiro T, Lewis N, Shaw PE, Cobb MH 1997 Cross-cascade activation of ERKs and ternary complex factors by Rho family proteins. *EMBO J* 16:6426–6438
- Sun H, King AJ, Diaz HB, Marshall MS 2000 Regulation of the protein kinase Raf-1 by oncogenic Ras through phosphatidylinositol 3-kinase, Cdc42/Rac and Pak. *Curr Biol* 10:281–284
- Chaudhary A, King WG, Mattaliano MD, Frost JA, Diaz B, Morrison DK, Cobb MH, Marshall MS, Brugge JS 2000

- Phosphatidylinositol 3-kinase regulates Raf1 through Pak phosphorylation of serine 338. *Curr Biol* 10:551-554
35. Sells MA, Knaus UG, Bagrodia S, Ambrose DM, Bokoch GM, Chernoff J 1997 Human p21-activated kinase (Pak1) regulates actin organization in mammalian cells. *Curr Biol* 7:202-210
36. Dharmawardane S, Sanders LC, Martin SS, Daniels RH, Bokoch GM 1997 Localization of p21-activated kinase 1 (PAK1) to pinocytotic vesicles and cortical actin structures in stimulated cells. *J Cell Biol* 138:1265-1278
37. Abo A, Qu J, Cammarano MS, Dan C, Fritsch A, Baud V, Belisle B, Minden A 1998 PAK4, a novel effector for Cdc42Hs, is implicated in the reorganization of the actin cytoskeleton and in the formation of filopodia. *EMBO J* 17:6527-6540
38. Faure S, Vigneron S, Galas S, Brassac T, Delsert C, Morin N 1999 Control of G2/M transition in *Xenopus* by a member of the p21-activated kinase (PAK) family: a link between protein kinase A and PAK signaling pathways? *J Biol Chem* 274:3573-3579
39. Leeuw T, Wu C, Schrag JD, Whiteway M, Thomas DY, Leberer E 1998 Interaction of a G-protein β -subunit with a conserved sequence in Ste20/PAK family protein kinases. *Nature* 391:191-195
40. Rudel T, Bokoch GM 1997 Membrane and morphological changes in apoptotic cells regulated by caspase-mediated activation of PAK2. *Science* 276:1571-1574
41. Lee N, MacDonald H, Reinhard C, Halenbeck R, Roulston A, Shi T, Williams LT 1997 Activation of hPAK65 by caspase cleavage induces some of the morphological and biochemical changes of apoptosis. *Proc Natl Acad Sci USA* 94:13642-13647
42. Walter BN, Huang Z, Jakobi R, Tuazon PT, Alnemri ES, Litwack G, Traugh JA 1998 Cleavage and activation of p21-activated protein kinase γ -PAK by CPP32 (caspase 3). Effects of autophosphorylation on activity. *J Biol Chem* 273:28733-28739
43. Schurmann A, Mooney AF, Sanders LC, Sells MA, Wang HG, Reed JC, Bokoch GM 2000 p21-Activated kinase 1 phosphorylates the death agonist bad and protects cells from apoptosis. *Mol Cell Biol* 20:453-461
44. Sun HQ, Yamamoto M, Mejillano M, Yin HL 1999 Gelsolin, a multifunctional actin regulatory protein. *J Biol Chem* 274:33179-33182
45. Yeh S, Chang C 1996 Cloning and characterization of a specific coactivator, ARA70, for the androgen receptor in human prostate cells. *Proc Natl Acad Sci USA* 93:5517-5521
46. Gao T, Brantley K, Bolu E, McPhaul MJ 1999 RFG (ARA70, ELE1) interacts with the human androgen receptor in a ligand-dependent fashion, but functions only weakly as a coactivator in cotransfection assays. *Mol Endocrinol* 13:1645-1656
47. Ozanne DM, Brady ME, Cook S, Gaughan L, Neal DE, Robson CN 2000 Androgen receptor nuclear translocation is facilitated by the f-actin cross-linking protein filamin. *Mol Endocrinol* 14:1618-1626
48. Hong H, Darimont BD, Ma H, Yang L, Yamamoto KR, Stallcup MR 1999 An additional region of coactivator GRIP1 required for interaction with the hormone-binding domains of a subset of nuclear receptors. *J Biol Chem* 274:3496-3502
49. Benner GE, Dennis PB, Masaracchia RA 1995 Activation of an S6/H4 kinase (PAK 65) from human placenta by intramolecular and intermolecular autophosphorylation. *J Biol Chem* 270:21121-21128
50. Brown JL, Stowers L, Baer M, Trejo J, Coughlin S, Chant J 1996 Human Ste20 homologue hPAK1 links GTPases to the JNK MAP kinase pathway. *Curr Biol* 6:598-605
51. Allen KM, Gleeson JG, Bagrodia S, Partington MW, MacMillan JC, Cerione RA, Mulley JC, Walsh CA 1998 PAK3 mutation in nonsyndromic X-linked mental retardation. *Nat Genet* 20:25-30
52. Lei M, Lu W, Meng W, Parrini MC, Eck MJ, Mayer BJ, Harrison SC 2000 Structure of PAK1 in an autoinhibited conformation reveals a multistage activation switch. *Cell* 102:387-397
53. Bokoch GM, Wang Y, Bohl BP, Sells MA, Quilliam LA, Knaus UG 1996 Interaction of the Nck adapter protein with p21-activated kinase (PAK1). *J Biol Chem* 271:25746-25749
54. Galisteo ML, Chernoff J, Su YC, Skolnik EY, Schlessinger J 1996 The adaptor protein Nck links receptor tyrosine kinases with the serine-threonine kinase Pak1. *J Biol Chem* 271:20997-21000
55. Lu W, Mayer BJ 1999 Mechanism of activation of Pak1 kinase by membrane localization. *Oncogene* 18:797-806
56. Wang J, Frost JA, Cobb MH, Ross EM 1999 Reciprocal signaling between heterotrimeric G proteins and the p21-stimulated protein kinase. *J Biol Chem* 274:31641-31647
57. Hong H, Kohli K, Garabedian MJ, Stallcup MR 1997 GRIP1, a transcriptional coactivator for the AF-2 transactivation domain of steroid, thyroid, retinoid, and vitamin D receptors. *Mol Cell Biol* 17:2735-2744
58. Fenton MA, Shuster TD, Fertig AM, Taplin ME, Kolvenbag G, Bubley GJ, Balk SP 1997 Functional characterization of mutant androgen receptors from androgen-independent prostate cancer. *Clin Cancer Res* 3:1383-1388
59. Veldscholte J, Ris-Stalpers C, Kuiper GG, Jenster G, Berrevoets C, Claassen E, van Rooij HC, Trapman J, Brinkmann AO, Mulder E 1990 A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. *Biochem Biophys Res Commun* 173:534-540
60. Feng W, Ribeiro RC, Wagner RL, Nguyen H, Apriletti JW, Fletterick RJ, Baxter JD, Kushner PJ, West BL 1998 Hormone-dependent coactivator binding to a hydrophobic cleft on nuclear receptors. *Science* 280:1747-1749
61. Brzozowski AM, Pike AC, Dauter Z, Hubbard RE, Bonn T, Engstrom O, Ohman L, Greene GL, Gustafsson JA, Carlquist M 1997 Molecular basis of agonism and antagonism in the oestrogen receptor. *Nature* 389:753-758
62. Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard DA, Greene GL 1998 The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. *Cell* 95:927-937
63. Halachmi S, Marden E, Martin G, MacKay H, Abbondanza C, Brown M 1994 Estrogen receptor-associated proteins: possible mediators of hormone-induced transcription. *Science* 264:1455-1458
64. Zhao ZS, Manser E, Chen XQ, Chong C, Leung T, Lim L 1998 A conserved negative regulatory region in α PAK: inhibition of PAK kinases reveals their morphological roles downstream of Cdc42 and Rac1. *Mol Cell Biol* 18:2153-2163
65. Frost JA, Khokhlatchev A, Stippes S, White MA, Cobb MH 1998 Differential effects of PAK1-activating mutations reveal activity-dependent and -independent effects on cytoskeletal regulation. *J Biol Chem* 273:28191-28198
66. Zenke FT, King CC, Bohl BP, Bokoch GM 1999 Identification of a central phosphorylation site in p21-activated kinase regulating autoinhibition and kinase activity. *J Biol Chem* 274:32565-32573
67. Brinkmann AO, Faber PW, van Rooij HC, Kuiper GG, Ris C, Klaassen P, van der Korput JA, Voorhorst MM, van Laar JH, Mulder E 1989 The human androgen receptor: domain structure, genomic organization and regulation of expression. *J Steroid Biochem* 34:307-310
68. Su LF, Knoblauch R, Garabedian MJ 2001 Rho GTPases as modulators of the estrogen receptor transcriptional response. *J Biol Chem* 276:3231-3237
69. Bourguet W, Ruff M, Chambon P, Gronemeyer H, Moras D 1995 Crystal structure of the ligand-binding

- domain of the human nuclear receptor RXR- α . *Nature* 375:377–382
70. Renaud JP, Rochel N, Ruff M, Vivat V, Chambon P, Gronemeyer H, Moras D 1995 Crystal structure of the RAR- γ ligand-binding domain bound to all-trans retinoic acid. *Nature* 378:681–689
71. Moilanen AM, Karvonen U, Poukka H, Janne OA, Palvimo JJ 1998 Activation of androgen receptor function by a novel nuclear protein kinase. *Mol Biol Cell* 9:2527–2543
72. Jackson TA, Richer JK, Bain DL, Takimoto GS, Tung L, Horwitz KB 1997 The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N-CoR or SMRT. *Mol Endocrinol* 11:693–705
73. Poukka H, Aarnisalo P, Karvonen U, Palvimo JJ, Janne OA 1999 Ubc9 interacts with the androgen receptor and activates receptor-dependent transcription. *J Biol Chem* 274:19441–19446
74. Wang Q, Lu J, Yong EL 2001 Ligand- and coactivator-mediated transactivation function (AF2) of the androgen receptor ligand-binding domain is inhibited by the cognate hinge region. *J Biol Chem* 276:7493–7499
75. Buchanan G, Yang M, Harris JM, Nahm HS, Han G, Moore N, Bentel JM, Matusik RJ, Horsfall DJ, Marshall VR, Greenberg NM, Tilley WD 2001 Mutations at the boundary of the hinge and ligand binding domain of the androgen receptor confer increased transactivation function. *Mol Endocrinol* 15:46–56
76. Yang F, Li X, Sharma M, Zarnegar M, Lim B, Sun Z 2001 Androgen receptor specifically interacts with a novel p21-activated kinase, PAK6. *J Biol Chem* 276:15345–15353
77. Melzig J, Rein KH, Schafer U, Pfister H, Jackle H, Heisenberg M, Raabe T 1998 A protein related to p21-activated kinase (PAK) that is involved in neurogenesis in the *Drosophila* adult central nervous system. *Curr Biol* 8:1223–1226
78. Manser E, Loo TH, Koh CG, Zhao ZS, Chen XQ, Tan L, Tan I, Leung T, Lim L 1998 PAK kinases are directly coupled to the PIX family of nucleotide exchange factors. *Mol Cell* 1:183–192
79. Bagrodia S, Taylor SJ, Jordon KA, Van Aelst L, Cerione RA 1998 A novel regulator of p21-activated kinases. *J Biol Chem* 273:23633–23636
80. Sun Z, Pan J, Balk SP 1997 Androgen receptor-associated protein complex binds upstream of the androgen-responsive elements in the promoters of human prostate-specific antigen and kallikrein 2 genes. *Nucleic Acids Res* 25:3318–3325
81. Tolia KF, Cantley LC, Carpenter CL 1995 Rho family GTPases bind to phosphoinositide kinases. *J Biol Chem* 270:17656–17659
82. Taplin ME, Bubley GJ, Shuster TD, Frantz ME, Spooner AE, Ogata GK, Keer HN, Balk SP 1995 Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. *N Engl J Med* 332:1393–1398
83. Takeshita A, Yen PM, Ikeda M, Cardona GR, Liu Y, Koibuchi N, Norwitz ER, Chin WW 1998 Thyroid hormone response elements differentially modulate the interactions of thyroid hormone receptors with two receptor binding domains in the steroid receptor coactivator-1. *J Biol Chem* 273:21554–21562

